
TY  - JOUR
TI  - E-Posters
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 102
IS  - s1
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.9730
DO  - doi:10.1002/bjs.9730
SP  - 127
EP  - 301
PY  - 2015
ER  - 

TY  - JOUR
TI  - 125th annual meeting: American Neurological Association
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 48
IS  - 3
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.410480301
DO  - doi:10.1002/ana.410480301
SP  - 407
EP  - 552
PY  - 2000
ER  - 

TY  - JOUR
TI  - Poster Presentation
JO  - Haemophilia
JA  - Haemophilia
VL  - 19
IS  - s2
SN  - 1351-8216
UR  - https://doi.org/10.1111/hae.12083
DO  - doi:10.1111/hae.12083
SP  - 10
EP  - 82
PY  - 2013
ER  - 

TY  - JOUR
TI  - American Epilepsy Society Proceedings
JO  - Epilepsia
VL  - 41
IS  - s7
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1157.2000.tb01727.x
DO  - doi:10.1111/j.1528-1157.2000.tb01727.x
SP  - 1
EP  - 256
PY  - 2000
ER  - 

TY  - JOUR
TI  - Poster Discussion Sessions
JO  - Allergy
VL  - 65
IS  - s92
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2010.02392.x
DO  - doi:10.1111/j.1398-9995.2010.02392.x
SP  - 78
EP  - 208
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - HIV Medicine
JA  - HIV Med
VL  - 19
IS  - S2
SN  - 1464-2662
UR  - https://doi.org/10.1111/hiv.12614
DO  - doi:10.1111/hiv.12614
SP  - s21
EP  - s152
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstraktband anlässlich der 44. Tagung der Deutschen Dermatologischen Gesellschaft Vereinigung Deutschsprachiger Dermatologen e. V. in Dresden vom 25. bis 28. April 2007
JO  - JDDG: Journal der Deutschen Dermatologischen Gesellschaft
VL  - 5
IS  - s2
SN  - 1610-0379
UR  - https://doi.org/10.1111/j.1610-0387.2007.06357.x
DO  - doi:10.1111/j.1610-0387.2007.06357.x
SP  - S1
EP  - S260
PY  - 2007
ER  - 

TY  - JOUR
TI  - Focused Conferences
JO  - Basic & Clinical Pharmacology & Toxicology
VL  - 107
IS  - s1
SN  - 1742-7835
UR  - https://doi.org/10.1111/j.1742-7843.2010.00598_2.x
DO  - doi:10.1111/j.1742-7843.2010.00598_2.x
SP  - 7
EP  - 70
PY  - 2010
ER  - 

TY  - JOUR
AU  - Mastellos, Dimitrios C.
AU  - Yancopoulou, Despina
AU  - Kokkinos, Petros
AU  - Huber-Lang, Markus
AU  - Hajishengallis, George
AU  - Biglarnia, Ali R.
AU  - Lupu, Florea
AU  - Nilsson, Bo
AU  - Risitano, Antonio M.
AU  - Ricklin, Daniel
AU  - Lambris, John D.
TI  - Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 45
IS  - 4
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.12419
DO  - doi:10.1111/eci.12419
SP  - 423
EP  - 440
KW  - clinical translation
KW  - complement-based drug design
KW  - compstatin
KW  - Cp40
KW  - nonhuman primate models
KW  - peptidic C3 inhibitors
PY  - 2015
AB  - Abstract There is a growing awareness that complement plays an integral role in human physiology and disease, transcending its traditional perception as an accessory system for pathogen clearance and opsonic cell killing. As the list of pathologies linked to dysregulated complement activation grows longer, it has become clear that targeted modulation of this innate immune system opens new windows of therapeutic opportunity for anti-inflammatory drug design. Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering with convertase formation and C3 cleavage. As the convergence point of all activation pathways and a molecular hub for crosstalk with multiple pathogenic pathways, C3 represents an attractive target for therapeutic modulation of the complement cascade. A multidisciplinary drug optimization effort encompassing rational ?wet? and in silico synthetic approaches and an array of biophysical, structural and analytical tools has culminated in an impressive structure-function refinement of compstatin, yielding a series of analogues that show promise for a wide spectrum of clinical applications. These new derivatives have improved inhibitory potency and pharmacokinetic profiles and show efficacy in clinically relevant primate models of disease. This review provides an up-to-date survey of the drug design effort placed on the compstatin family of C3 inhibitors, highlighting the most promising drug candidates. It also discusses translational challenges in complement drug discovery and peptide drug development and reviews concerns related to systemic C3 interception.
ER  - 

TY  - JOUR
TI  - Oral E-Posters
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 106
IS  - S5
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.11341
DO  - doi:10.1002/bjs.11341
SP  - 48
EP  - 84
PY  - 2019
ER  - 

TY  - JOUR
TI  - THSNA 2018 Summit Abstract Proceedings
JO  - American Journal of Hematology
JA  - Am J Hematol
VL  - 93
IS  - 9
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.25268
DO  - doi:10.1002/ajh.25268
SP  - E253
EP  - E328
PY  - 2018
ER  - 

TY  - JOUR
TI  - POSTER PRESENTATION: BILIARY
JO  - HPB
VL  - 14
IS  - s2
SN  - 1365-182X
UR  - https://doi.org/10.1111/j.1477-2574.2012.00512.x
DO  - doi:10.1111/j.1477-2574.2012.00512.x
SP  - 288
EP  - 699
PY  - 2012
ER  - 

TY  - JOUR
TI  - International Society of Paediatric Oncology SIOP 2007: Contents and Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 49
IS  - 4
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.21342
DO  - doi:10.1002/pbc.21342
SP  - 398
EP  - 605
PY  - 2007
AB  - Abstract The Full online issue can be found at http://www.interscience.wiley.com/jpages/1545-5009/suppmat
ER  - 

TY  - JOUR
TI  - P01. Posters 1
JO  - Australasian Journal of Dermatology
VL  - 38
IS  - S2
SN  - 0004-8380
UR  - https://doi.org/10.1111/ajd.1997.38.s2.77
DO  - doi:10.1111/ajd.1997.38.s2.77
SP  - 77
EP  - 124
PY  - 1997
ER  - 

TY  - JOUR
TI  - European Tissue Repair Society Annual Meeting — 2019 Isarforum Munich, Germany September 11th – September 13th, 2019 “Tissue regeneration: From basic science to clinical translation” On the processes of fibrosis, wound care and scar management
JO  - Wound Repair and Regeneration
JA  - Wound Rep Reg
VL  - n/a
IS  - n/a
SN  - 1067-1927
UR  - https://doi.org/10.1111/wrr.12772
DO  - doi:10.1111/wrr.12772
ER  - 

TY  - JOUR
TI  - Abstracts - AAPA Presentations
JO  - American Journal of Physical Anthropology
JA  - Am. J. Phys. Anthropol.
VL  - 156
IS  - S60
SN  - 0002-9483
UR  - https://doi.org/10.1002/ajpa.22718
DO  - doi:10.1002/ajpa.22718
SP  - 65
EP  - 334
PY  - 2015
ER  - 

TY  - JOUR
TI  - 135th Annual Meeting Poster Session AbstractsMonday, September 13, 2010
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 68
IS  - S14
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.22175
DO  - doi:10.1002/ana.22175
SP  - S4
EP  - S62
PY  - 2010
ER  - 

TY  - JOUR
AU  - Castori, Marco
AU  - Morlino, Silvia
AU  - Celletti, Claudia
AU  - Celli, Mauro
AU  - Morrone, Aldo
AU  - Colombi, Marina
AU  - Camerota, Filippo
AU  - Grammatico, Paola
TI  - Management of pain and fatigue in the joint hypermobility syndrome (a.k.a. Ehlers–Danlos syndrome, hypermobility type): Principles and proposal for a multidisciplinary approach
JO  - American Journal of Medical Genetics Part A
JA  - Am. J. Med. Genet.
VL  - 158A
IS  - 8
SN  - 1552-4825
UR  - https://doi.org/10.1002/ajmg.a.35483
DO  - doi:10.1002/ajmg.a.35483
SP  - 2055
EP  - 2070
KW  - disability
KW  - Ehlers–Danlos syndrome
KW  - joint hypermobility
KW  - multidisciplinary
KW  - physical therapy
KW  - treatment
PY  - 2012
AB  - Abstract Joint hypermobility syndrome (JHS), or Ehlers?Danlos syndrome (EDS) hypermobility type (EDS-HT), is a underdiagnosed heritable connective tissue disorder characterized by generalized joint hypermobility and a wide range of visceral, pelvic, neurologic, and cognitive dysfunctions. Deterioration of quality of life is mainly associated with pain and fatigue. Except for the recognized effectiveness of physiotherapy for some musculoskeletal features, there are no standardized guidelines for the assessment and treatment of pain and fatigue. In this work, a practical classification of pain presentations and factors contributing in generating painful sensations in JHS/EDS-HT is proposed. Pain can be topographically classified in articular limb (acute/subacute and chronic), muscular limb (myofascial and fibromyalgia), neuropathic limb, back/neck, abdominal and pelvic pain, and headache. For selected forms of pain, specific predisposing characteristics are outlined. Fatigue appears as the result of multiple factors, including muscle weakness, respiratory insufficiency, unrefreshing sleep, dysautonomia, intestinal malabsorption, reactive depression/anxiety, and excessive use of analgesics. A set of lifestyle recommendations to instruct patients as well as specific investigations aimed at characterizing pain and fatigue are identified. Available treatment options are discussed in the set of a structured multidisciplinary approach based on reliable outcome tools. ? 2012 Wiley Periodicals, Inc.
ER  - 

TY  - JOUR
TI  - Poster Sessions 2
JO  - Allergy
VL  - 67
IS  - s96
SN  - 0105-4538
UR  - https://doi.org/10.1111/all.12036
DO  - doi:10.1111/all.12036
SP  - 307
EP  - 451
PY  - 2012
ER  - 

TY  - JOUR
TI  - Concurrent Oral Sessions: Other
JO  - American Journal of Transplantation
VL  - 14
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.12883
DO  - doi:10.1111/ajt.12883
SP  - 196
EP  - 208
PY  - 2014
ER  - 
